CSIMarket
 


Allakos Inc   (ALLK)
Other Ticker:  
 

Allakos Inc 's Working Capital Ratio

ALLK's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




ALLK Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change -32.09 % 7.37 % 64.08 % 112.51 % 107.48 %
Y / Y Current Assets Change -36.17 % -61.49 % -58.95 % 6.31 % 15.97 %
Working Capital Ratio MRQ 12.3 6.08 6.87 11.22 13.08
Overall Ranking # # # # #
Seq. Current Liabilities Change -24.42 % -2.79 % -6.7 % -0.92 % 19.49 %
Seq. Current Assets Change 52.89 % -14.06 % -42.83 % -15.03 % -7.74 %



Working Capital Ratio third quarter 2022 Comment
Allakos Inc 's Current Assets grew by 52.89 % in the III. Quarter sequntially, while Current Liabilities decreased, this led to improvement in Allakos Inc 's Working Capital Ratio to 12.3, above Allakos Inc average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry Allakos Inc booked the highest Working Capital Ratio than Allakos Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is ALLK most successful ?
Working Capital Ratio ALLK on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Allakos Inc 's Current Liabilities $ 28 Millions Visit ALLK's Balance sheet
Allakos Inc 's Current Assets $ 339 Millions Visit ALLK's Balance sheet
Source of ALLK's Sales Visit ALLK's Sales by Geography


Cumulative Allakos Inc 's Working Capital Ratio

ALLK's Working Capital Ratio for the trailling 12 Months

ALLK Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth -32.09 % 7.37 % 64.08 % 112.51 % 107.48 %
Y / Y Current Assets TTM Growth -36.17 % -61.49 % -58.95 % 6.31 % 15.97 %
Working Capital Ratio TTM 8.96 9.44 11.92 15.88 18.56
Total Ranking TTM # 182 # 178 # 469 # 205 # 465
Seq. Current Liabilities TTM Growth -24.42 % -2.79 % -6.7 % -0.92 % 19.49 %
Seq. Current Assets TTM Growth 52.89 % -14.06 % -42.83 % -15.03 % -7.74 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis In spite of the year on year decrease in ALLK's average Current Liabilities to $27.59 millions, Working Capital Ratio to 8.96 below company average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 79 other companies have achieved higher Working Capital Ratio than Allakos Inc . While overall ranking remained unchanged compare to previous quarter at no. 182.

Explain Working Capital Ratio
Where is ALLK most successful ?
Working Capital Ratio ALLK on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 80
Healthcare Sector # 128
Within the Market # 182


TTM Working Capital Ratio Statistics
High Average Low
33.7 22.38 8.96
(Mar 31 2020)   (Sep 30 2022)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Design Therapeutics Inc   33.47 $ 348.488  Millions$ 10.412  Millions
Kezar Life Sciences Inc   31.15 $ 298.927  Millions$ 9.595  Millions
Merrimack Pharmaceuticals Inc  30.42 $ 13.628  Millions$ 0.448  Millions
Karuna Therapeutics Inc   29.93 $ 1,219.678  Millions$ 40.745  Millions
Nextcure Inc   29.76 $ 175.315  Millions$ 5.891  Millions
Anebulo Pharmaceuticals Inc  28.38 $ 19.815  Millions$ 0.698  Millions
Theseus Pharmaceuticals inc   27.54 $ 214.997  Millions$ 7.806  Millions
Spruce Biosciences Inc   27.43 $ 93.186  Millions$ 3.397  Millions
Cyteir Therapeutics Inc   27.05 $ 157.348  Millions$ 5.816  Millions
Savara Inc   26.55 $ 137.069  Millions$ 5.163  Millions
Imago Biosciences Inc   25.95 $ 182.040  Millions$ 7.015  Millions
Ironwood Pharmaceuticals inc   25.78 $ 698.994  Millions$ 27.117  Millions
Terns Pharmaceuticals Inc   25.47 $ 190.537  Millions$ 7.481  Millions
Oramed Pharmaceuticals Inc   25.44 $ 160.172  Millions$ 6.297  Millions
Nanoviricides inc   25.37 $ 13.153  Millions$ 0.518  Millions
Eqrx Inc   25.33 $ 1,523.990  Millions$ 60.163  Millions
Infinity Pharmaceuticals Inc   25.28 $ 49.350  Millions$ 1.952  Millions
Morphic Holding inc   25.09 $ 382.410  Millions$ 15.241  Millions
Io Biotech Inc   24.96 $ 157.751  Millions$ 6.321  Millions
Diamedica Therapeutics Inc   24.31 $ 36.490  Millions$ 1.501  Millions
Pasithea Therapeutics Corp   24.21 $ 44.469  Millions$ 1.837  Millions
Seres Therapeutics Inc   23.69 $ 247.513  Millions$ 10.449  Millions
Anaptysbio inc  23.15 $ 450.444  Millions$ 19.459  Millions
Dice Therapeutics Inc   22.96 $ 267.837  Millions$ 11.665  Millions
Pmv Pharmaceuticals Inc   22.75 $ 265.176  Millions$ 11.656  Millions
Eliem Therapeutics Inc   22.46 $ 133.171  Millions$ 5.928  Millions
Keros Therapeutics Inc   22.21 $ 245.875  Millions$ 11.070  Millions
Cassava Sciences Inc   22.06 $ 183.272  Millions$ 8.308  Millions
Janux Therapeutics Inc   21.08 $ 344.330  Millions$ 16.335  Millions
Ovid Therapeutics Inc   20.88 $ 140.537  Millions$ 6.732  Millions

Date modified: 2022-11-08T18:10:25+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

REPX's Profile

Stock Price

REPX's Financials

Business Description

Fundamentals

Charts & Quotes

REPX's News

Suppliers

REPX's Competitors

Customers & Markets

Economic Indicators

REPX's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071